Compare Invesco S&P 500 High Div Low Volatility ETF (SPHD) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco S&P 500 High Div Low Volatility ETF vs Viatris Inc — how do they compare? Invesco S&P 500 High Div Low Volatility ETF trades at $48.71 (market cap $3.14B), while Viatris Inc trades at $17.47 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 6.4× Invesco S&P 500 High Div Low Volatility ETF's market cap, and Viatris Inc pays a 2.75% dividend while Invesco S&P 500 High Div Low Volatility ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco S&P 500 High Div Low Volatility ETF for 125 Days and Viatris Inc for 57 Days on average.
| SPHD | VTRS | |
|---|---|---|
Market Cap | $3.14B | $20.03B |
Volume | 1,461,349 | 14,109,977 |
52-Week High | $53.55 | $18.27 |
52-Week Low | $46.96 | $9.74 |
Typical Hold Time | 125 Days | 57 Days |
Sector | — | Health |
Enterprise Value | — | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPHD trades at $48.19, down 0.58% on the day, with a bearish technical signal driven by moving averages. The ETF focuses on high-dividend, low-volatility S&P 500 stocks, offering monthly income but facing criticism for weaker total returns compared to peers like SCHD. Recent dividends of $0.20 and $0.21 were declared for 2026, emphasizing its income-oriented strategy.
Outlook is cautious due to underperformance risks and lack of quality filters in stock selection. Opportunities include reliable monthly dividends for retirees, but risks involve yield traps and market volatility. Investors should weigh income needs against growth potential.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal and strong recent earnings beats. The company shows improving operational cash flow of $2.32B in 2025 and positive revenue growth trends, though profitability remains challenged with negative net margins. Recent developments include FDA approval for WAKIX in Japan and consistent dividend payments, supporting the bullish analyst consensus with a $22.17 price target representing 27% upside potential.
The outlook remains cautiously optimistic with strong cash generation supporting shareholder returns, but investors face risks from persistent negative profitability and high debt levels. The stock offers value appeal with reasonable P/S and P/B ratios, though the elevated P/E ratio reflects current earnings challenges that need resolution for sustained re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco S&P 500 High Div Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
